Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

Psychedelic Stock Market Update | January 2022

Feb 4 • 4 min read

The past few months haven’t been kind to psychedelic investors and January was no exception. In 2021, we saw three companies IPO at a greater than $1 billion valuation. This includes Compass Pathways (CMPS), GH Research (GHRS), and ATAI Life Sciences (ATAI). We also saw MindMed (MNMD), which first went public in 2020, break the…

Over $730M Was Invested in Psychedelics in 2021

Jan 18 • 47 min read

You may know Psychedelic Invest for our trackable index of public companies. You may know us for our constant stream of informative content surrounding the financial side of this growing industry. You might even know us from the epic parties we got to throw in-person again this year.

However you may know us now, the value that we deliver to readers like you is about to expand exponentially in 2022.

Is This the End of Patents on Psilocybin?

Jan 7 • 3 min read

COMPASS Pathways (CMPS)—a leader in the emerging psychedelic therapies space—got dealt a huge blow last week as one of its patents for lab-created psilocybin was formally called into question. On December 15, nonprofit organization Freedom to Operate (FTO) filed a petition essentially claiming that the company’s synthetic psilocybin isn’t a new invention, and therefore can’t…

2021: The Year in Psychedelics

Dec 31 • 3 min read

2021 was an expansive year for the psychedelics industry, topping the previous year of immense growth, with funding to psychedelic medicine companies surpassing $730M across 61 total deals, up from 42 in 2020–in what some are calling “The Psychedelic Renaissance.” Public and private organizations are driving the psychedelic reform movement internationally, with companies and lawmakers…

What Happened Last Week with the Market?: A Look at Compass Pathways and Clinical Results

Nov 17 • 4 min read

This article has been written by Jessica Stewart. Everything written herein is personal thoughts and opinions of the writer. Jessica’s bio can be found at the bottom of the article. Last week, Compass Pathways released the highly-anticipated topline results from their Phase 11b trial of psilocybin for Treatment Resistance Depression (TRD). We all waited with…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354